1. Home
  2. People
  3. Faculty
  4. James Liao

James Liao

Professor
jliao@medicine.bsd.uchicago.edu
Research Summary
Dr. Liao is the Harold H. Hines Jr. Professor of Medicine and Chief of Cardiology Section at the University of Chicago. He is also the Director of the Physician Scientist Development Program and Principal Investigator of the NIH T32 Cardiovascular Sciences Training Grant. His laboratory has made many important discoveries, which has helped elucidate signaling mechanisms in the vascular wall. Specifically, his laboratory explored molecular pathways which revealed how HMG-CoA reductase inhibitors (or statins) could exert cholesterol-independent or "pleiotropic" effects. This translational work provided a mechanistic basis for the benefit of statin therapy in stroke patients for which he received and was awarded the Cardiovascular Research Prize from the American Heart Association. His laboratory also identified, cloned, and characterized a novel cytochrome P450 epoxygenase, CYP2J2, and its products, epoxyeicosatrienoic acids (EETs), as endothelium-derived hyporpolarizing factors with anti-inflammatory and anti-ischemic properties. In addition, his work also led to the discovery of a novel, rapid, nongenomic effect of steroid hormone receptors. For his research accomplishments, Dr. Liao received the Jeffrey M. Hoeg Arteriosclerosis, Thrombosis, and Vascular Biology Award from the American Heart Association and the Outstanding Investigator Award from the American Federation for Medical Research. He has served on numerous NIH study sections, advisory committees, and special emphasis panels.
Biosciences Graduate Program Association
Publications

  1. Tie2-Cre-Induced Inactivation of Non-Nuclear Estrogen Receptor-a Signaling Abrogates Estrogen Protection?Against Vascular Injury. JACC Basic Transl Sci. 2023 Jan; 8(1):55-67. View in: PubMed

  2. Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in?BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC CardioOncol. 2022 Sep; 4(3):371-383. View in: PubMed

  3. Vascular Stiffening Mediated by Rho-Associated Coiled-Coil Containing Kinase Isoforms. J Am Heart Assoc. 2021 10 19; 10(20):e022568. View in: PubMed

  4. Challenging Statin Pleiotropy: Preeclampsia. Circulation. 2021 08 31; 144(9):680-683. View in: PubMed

  5. Increase in Blood-Brain Barrier (BBB) Permeability Is Regulated by MMP3 via the ERK Signaling Pathway. Oxid Med Cell Longev. 2021; 2021:6655122. View in: PubMed

  6. Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res. 2022 01 29; 118(2):413-423. View in: PubMed

  7. SALAD-BAAR: A numerical risk score for hospital admission or emergency department presentation in ambulatory patients with cardiovascular disease. Clin Cardiol. 2021 Feb; 44(2):193-199. View in: PubMed

  8. Regulator of G-Protein Signaling 5 Maintains Brain Endothelial Cell Function in Focal Cerebral Ischemia. J Am Heart Assoc. 2020 09 15; 9(18):e017533. View in: PubMed

  9. Serine-threonine kinase ROCK2 regulates germinal center B cell positioning and cholesterol biosynthesis. J Clin Invest. 2020 07 01; 130(7):3654-3670. View in: PubMed

  10. Community Health Workers Reduce Rehospitalizations and Emergency Department Visits for Low-Socioeconomic Urban Patients With Heart Failure. Crit Pathw Cardiol. 2020 09; 19(3):139-145. View in: PubMed

  11. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. Expert Opin Ther Targets. 2020 01; 24(1):47-62. View in: PubMed

  12. A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. Transl Stroke Res. 2020 06; 11(3):365-376. View in: PubMed

  13. Association of Rising Violent Crime With Blood Pressure and Cardiovascular Risk: Longitudinal Evidence From Chicago, 2014-2016. Am J Hypertens. 2019 11 15; 32(12):1192-1198. View in: PubMed

  14. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744. View in: PubMed

  15. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853. View in: PubMed

  16. Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study. J Hypertens. 2019 05; 37(5):1083-1095. View in: PubMed

  17. The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Curr Vasc Pharmacol. 2019; 17(3):222-232. View in: PubMed

  18. Impaired Cognitive Performance in Endothelial Nitric Oxide Synthase Knockout Mice After Ischemic Stroke: A Pilot Study. Am J Phys Med Rehabil. 2018 07; 97(7):492-499. View in: PubMed

  19. Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice. Circ J. 2018 03 23; 82(4):1195-1204. View in: PubMed

  20. The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2018 04; 58(4):471-481. View in: PubMed

  21. ROCK as a therapeutic target for ischemic stroke. Expert Rev Neurother. 2017 Dec; 17(12):1167-1177. View in: PubMed

  22. Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight. 2017 Jul 06; 2(13). View in: PubMed

  23. Tumor necrosis factor-a levels and non-surgical bleeding in continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2018 01; 37(1):107-115. View in: PubMed

  24. Cardiology Consultation in the Emergency Department Reduces Re-hospitalizations for Low-Socioeconomic Patients with Acute Decompensated Heart Failure. Am J Med. 2017 09; 130(9):1112.e17-1112.e31. View in: PubMed

  25. Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets. Cardiovasc Res. 2017 Sep 01; 113(11):1307-1317. View in: PubMed

  26. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017 Jan 06; 120(1):229-243. View in: PubMed

  27. Role of ROCK2 in CD4+ cells in allergic airways responses in mice. Clin Exp Allergy. 2017 Feb; 47(2):224-235. View in: PubMed

  28. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194. View in: PubMed

  29. MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation. Vascul Pharmacol. 2016 09; 84:67-73. View in: PubMed

  30. Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. Circulation. 2016 Jul 12; 134(2):141-52. View in: PubMed

  31. Rho Kinases and Cardiac Remodeling. Circ J. 2016 Jun 24; 80(7):1491-8. View in: PubMed

  32. Interventional Transcatheter Closure Ameliorates the Leukocyte Rho Kinase Activities among Patients with Patent Ductus Arteriosus. Acta Cardiol Sin. 2015 Nov; 31(6):494-9. View in: PubMed

  33. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578. View in: PubMed

  34. Relative Lack of Culprit and Obstructive Coronary Lesions in Patients With Acute Ischemic Stroke and Elevated Cardiac Troponin. Circulation. 2016 Mar 29; 133(13):1228-9. View in: PubMed

  35. Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64. View in: PubMed

  36. Rho-associated kinase activity is an independent predictor of cardiovascular events in acute coronary syndrome. Hypertension. 2015 Oct; 66(4):892-9. View in: PubMed

  37. ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. Am J Physiol Lung Cell Mol Physiol. 2015 Oct 01; 309(7):L736-46. View in: PubMed

  38. MnTBAP stimulates angiogenic functions in endothelial cells through mitofusin-1. Vascul Pharmacol. 2015 Sep; 72:163-71. View in: PubMed

  39. Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial. Hypertens Res. 2015 Jul; 38(7):485-90. View in: PubMed

  40. Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism. Hypertension. 2015 Apr; 65(4):841-8. View in: PubMed

  41. Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression. J Mol Cell Cardiol. 2015 Feb; 79:180-6. View in: PubMed

  42. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015; 67(1):103-17. View in: PubMed

  43. Abrogation of airway hyperresponsiveness but not inflammation by rho kinase insufficiency. Clin Exp Allergy. 2015 Feb; 45(2):457-70. View in: PubMed

  44. Critical role of exogenous nitric oxide in ROCK activity in vascular smooth muscle cells. PLoS One. 2014; 9(10):e109017. View in: PubMed

  45. Evidence of pleiotropy by statins: leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. Int J Cardiol. 2014 Sep; 176(1):250-3. View in: PubMed

  46. Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother. 2014 Feb; 14(2):173-85. View in: PubMed

  47. Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension. 2014 Apr; 63(4):856-64. View in: PubMed

  48. Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study. Clin Sci (Lond). 2014 Jun; 126(12):829-835. View in: PubMed

  49. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal. 2014 Mar 10; 20(8):1251-67. View in: PubMed

  50. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol. 2013 Jul; 33(7):1591-600. View in: PubMed

  51. Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J Sex Med. 2013 Jun; 10(6):1502-15. View in: PubMed

  52. Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease. Clin Cardiol. 2013 Jun; 36(6):347-51. View in: PubMed

  53. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest. 2013 Feb; 123(2):540-1. View in: PubMed

  54. FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J. 2013 Apr; 27(4):1439-49. View in: PubMed

  55. Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One. 2012; 7(11):e47842. View in: PubMed

  56. Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury. Vasc Med. 2012 Dec; 17(6):379-85. View in: PubMed

  57. Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation. 2012 Oct 30; 126(18):2236-47. View in: PubMed

  58. ROCK1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression. Curr Mol Med. 2013 Jan; 13(1):205-19. View in: PubMed

  59. ROCKs as immunomodulators of stroke. Expert Opin Ther Targets. 2012 Oct; 16(10):1013-25. View in: PubMed

  60. A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. Int J Cardiol. 2013 Sep 10; 167(6):2813-9. View in: PubMed

  61. Increased Rho kinase activity in congestive heart failure. Eur J Heart Fail. 2012 Sep; 14(9):965-73. View in: PubMed

  62. Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. Atherosclerosis. 2012 Apr; 221(2):521-6. View in: PubMed

  63. Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. Trends Cardiovasc Med. 2010 Oct; 20(7):228-31. View in: PubMed

  64. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther. 2012 Feb; 91(2):289-97. View in: PubMed

  65. A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol. 2012; 821:421-33. View in: PubMed

  66. Mitohormesis: another pleiotropic effect of statins? Eur Heart J. 2012 Jun; 33(11):1299-301. View in: PubMed

  67. Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011 Oct; 31(10):2353-9. View in: PubMed

  68. ROCK inhibition prevents fetal serum-induced alteration in structure and function of organ-cultured mesenteric artery. J Muscle Res Cell Motil. 2011 Sep; 32(2):65-76. View in: PubMed

  69. Role of Rho kinase isoforms in murine allergic airway responses. Eur Respir J. 2011 Oct; 38(4):841-50. View in: PubMed

  70. Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation. 2011 May 10; 123(18):1925-8. View in: PubMed

  71. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Hum Mol Genet. 2011 Jun 15; 20(12):2344-55. View in: PubMed

  72. Nuclear run-on assay to study gene transcription in vascular cells. Methods Mol Med. 1999; 30:151-7. View in: PubMed

  73. Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation. 2011 Mar 01; 123(8):866-76. View in: PubMed

  74. Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF. Lab Invest. 2011 May; 91(5):691-703. View in: PubMed

  75. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011 Jan; 69(1):119-29. View in: PubMed

  76. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011 Mar; 32(3):167-73. View in: PubMed

  77. Elevated homocysteine and C-reactive protein levels independently predict worsening prognosis after stroke in Chinese patients. J Huazhong Univ Sci Technolog Med Sci. 2010 Oct; 30(5):643-7. View in: PubMed

  78. Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens. 2011 Feb; 29(2):373-9. View in: PubMed

  79. Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis. 2011 Jan; 214(1):117-21. View in: PubMed

  80. NF-?B and innate immunity in ischemic stroke. Ann N Y Acad Sci. 2010 Oct; 1207:32-40. View in: PubMed

  81. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest. 2010 Sep; 120(9):3280-95. View in: PubMed

  82. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. 2010 Aug; 15(15-16):622-9. View in: PubMed

  83. Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J. 2010 May; 74(5):818-26. View in: PubMed

  84. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010 Sep; 24(9):3186-95. View in: PubMed

  85. Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury in hypercholesterolemic mice. Circulation. 2010 Mar 09; 121(9):1104-12. View in: PubMed

  86. Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers. Hypertens Res. 2010 Apr; 33(4):354-9. View in: PubMed

  87. Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol. 2010 Apr; 10(2):116-21. View in: PubMed

  88. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des. 2009; 15(27):3108-15. View in: PubMed

  89. Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev Neurother. 2009 Aug; 9(8):1171-86. View in: PubMed

  90. Genetically elevated C-reactive protein and ischemic vascular disease. Curr Atheroscler Rep. 2009 Jul; 11(4):245. View in: PubMed

  91. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Curr Atheroscler Rep. 2009 Jul; 11(4):243-4. View in: PubMed

  92. Smooth muscle Notch1 mediates neointimal formation after vascular injury. Circulation. 2009 May 26; 119(20):2686-92. View in: PubMed

  93. gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 2009 May 29; 383(2):216-21. View in: PubMed

  94. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal. 2009 Mar 17; 2(62):ra11. View in: PubMed

  95. Rac1 is a critical mediator of endothelium-derived neurotrophic activity. Sci Signal. 2009 Mar 10; 2(61):ra10. View in: PubMed

  96. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009; 15(5):467-78. View in: PubMed

  97. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol. 2009 Feb 15; 103(4):437-41. View in: PubMed

  98. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009 Aug; 205(2):517-21. View in: PubMed

  99. Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res. 2009 Feb 27; 1257:89-93. View in: PubMed

  100. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009 Jan 06; 119(1):131-8. View in: PubMed

  101. Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal. 2008 Nov 25; 1(47):ra14. View in: PubMed

  102. Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation. 2008 Nov 18; 118(21):2166-73. View in: PubMed

  103. Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. Can J Physiol Pharmacol. 2008 Sep; 86(9):633-42. View in: PubMed

  104. Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res. 2008 Sep 12; 103(6):591-7. View in: PubMed

  105. Fine-tuning the angiogenic response to vascular endothelial growth factor. Circ Res. 2008 Aug 01; 103(3):229-30. View in: PubMed

  106. Effect of torcetrapib in patients at high risk for coronary events. Curr Atheroscler Rep. 2008 Aug; 10(4):282. View in: PubMed

  107. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. Curr Atheroscler Rep. 2008 Aug; 10(4):281. View in: PubMed

  108. Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res. 2008 Aug 15; 103(4):360-8. View in: PubMed

  109. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J. 2008 Oct; 22(10):3561-70. View in: PubMed

  110. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest. 2008 May; 118(5):1632-44. View in: PubMed

  111. Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab. 2008 Jul; 28(7):1285-93. View in: PubMed

  112. A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol. 2008; 439:181-9. View in: PubMed

  113. Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci U S A. 2008 Mar 25; 105(12):4856-61. View in: PubMed

  114. Dynamic regulation of endothelial NOS mediated by competitive interaction with alpha-actinin-4 and calmodulin. FASEB J. 2008 May; 22(5):1450-7. View in: PubMed

  115. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):s39-42. View in: PubMed

  116. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008 Jan; 14(1):37-44. View in: PubMed

  117. Is statin discontinuation an option in patients who have had a stroke? Nat Clin Pract Neurol. 2008 Jan; 4(1):18-9. View in: PubMed

  118. Does it matter whether or not a lipid-lowering agent inhibits Rho kinase? Curr Atheroscler Rep. 2007 Nov; 9(5):384-8. View in: PubMed

  119. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007 Jul; 50(1):17-24. View in: PubMed

  120. Distribution of sphingosine kinase activity and mRNA in rodent brain. J Neurochem. 2007 Oct; 103(2):509-17. View in: PubMed

  121. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation. 2007 Jun 26; 115(25):3197-204. View in: PubMed

  122. Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol. 2007 Apr 17; 49(15):1619-1624. View in: PubMed

  123. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation. 2007 Mar 27; 115(12):1615-21. View in: PubMed

  124. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007 Feb 13; 49(6):698-705. View in: PubMed

  125. Safety and efficacy of statins in Asians. Am J Cardiol. 2007 Feb 01; 99(3):410-4. View in: PubMed

  126. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol. 2007 Apr; 292(4):H1937-42. View in: PubMed

  127. Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res. 2007 Jan 05; 100(1):70-8. View in: PubMed

  128. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res. 2006 Dec 08; 99(12):1426-32. View in: PubMed

  129. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab. 2007 May; 27(5):998-1009. View in: PubMed

  130. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A. 2006 Sep 19; 103(38):14104-9. View in: PubMed

  131. Rho-kinase: a potential link between hypercholesterolemia and abnormal vascular smooth muscle contraction. Circ Res. 2006 Aug 04; 99(3):238-9. View in: PubMed

  132. FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res. 2006 Sep 01; 99(5):468-76. View in: PubMed

  133. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 2006 Jun; 85(6):520-3. View in: PubMed

  134. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006 May 09; 103(19):7432-7. View in: PubMed

  135. Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1997-2006. View in: PubMed

  136. Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res. 2006 May 12; 98(9):1134-40. View in: PubMed

  137. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006 Mar; 290(3):C661-8. View in: PubMed

  138. Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest. 2006 Feb; 116(2):334-43. View in: PubMed

  139. Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol. 2006 Mar 14; 71(6):806-17. View in: PubMed

  140. Rho GTPases, statins, and nitric oxide. Circ Res. 2005 Dec 09; 97(12):1232-5. View in: PubMed

  141. Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005 Dec; 16(6):624-9. View in: PubMed

  142. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation. 2005 Nov 08; 112(19):2959-65. View in: PubMed

  143. Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med. 2005 Nov; 2(11):576-84. View in: PubMed

  144. Role of angiotensin II receptor subtypes in porcine basilar artery: functional, radioligand binding, and cell culture studies. Life Sci. 2006 Jan 25; 78(9):943-9. View in: PubMed

  145. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005 Oct; 36(10):2251-7. View in: PubMed

  146. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005 Sep 05; 96(5A):24F-33F. View in: PubMed

  147. Statins: potent vascular anti-inflammatory agents. Int J Clin Pract Suppl. 2004 Oct; (143):41-8. View in: PubMed

  148. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation. 2005 Jun 21; 111(24):3261-8. View in: PubMed

  149. ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther. 2005 May; 3(3):441-51. View in: PubMed

  150. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118. View in: PubMed

  151. Essential role of endothelial Notch1 in angiogenesis. Circulation. 2005 Apr 12; 111(14):1826-32. View in: PubMed

  152. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005 Jun; 25(6):722-9. View in: PubMed

  153. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 2004 May; 52(4):248-53. View in: PubMed

  154. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2004 Dec; 24(12):2238-44. View in: PubMed

  155. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004 Oct 12; 110(15):2132-6. View in: PubMed

  156. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004 Oct; 24(10):1842-7. View in: PubMed

  157. Statins and myocardial hypertrophy. Coron Artery Dis. 2004 Aug; 15(5):247-50. View in: PubMed

  158. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004 Jun; 39(6):1178-85. View in: PubMed

  159. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res. 2004 Jul 23; 95(2):217-23. View in: PubMed

  160. Statin therapy: having the good without the bad. Hypertension. 2004 Jun; 43(6):1171-2. View in: PubMed

  161. Targeting eNOS for stroke protection. Trends Neurosci. 2004 May; 27(5):283-9. View in: PubMed

  162. Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol. 2004 Mar; 43(3):454-61. View in: PubMed

  163. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des. 2004; 10(8):893-8. View in: PubMed

  164. Non-nuclear actions of estrogen: new targets for prevention and treatment of cardiovascular disease. Mol Interv. 2002 Jul; 2(4):219-28. View in: PubMed

  165. Lipid management with statins. The lower the better? Z Kardiol. 2004 Jan; 93(1):4-9. View in: PubMed

  166. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res. 2003 Nov 01; 60(2):250-8. View in: PubMed

  167. 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett. 2003 Nov 17; 13(22):4011-4. View in: PubMed

  168. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003; 35(6):398-403. View in: PubMed

  169. Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003 Aug 20; 42(4):690-7. View in: PubMed

  170. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003 Sep; 5(5):372-8. View in: PubMed

  171. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003 Aug; 23(16):5726-37. View in: PubMed

  172. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003 Aug 19; 108(7):839-43. View in: PubMed

  173. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol. 2003 Jul; 35(7):851-9. View in: PubMed

  174. Role of statin pleiotropism in acute coronary syndromes and stroke. Int J Clin Pract Suppl. 2003 Mar; (134):51-7. View in: PubMed

  175. Nontranscriptional actions of the glucocorticoid receptor. J Mol Med (Berl). 2003 Mar; 81(3):168-74. View in: PubMed

  176. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003 May 01; 23(5):729-36. View in: PubMed

  177. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol. 2003 Mar; 41(3):474-80. View in: PubMed

  178. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol. 2003 Feb 01; 23(2):198-203. View in: PubMed

  179. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol. 2003 Feb 01; 23(2):156-7. View in: PubMed

  180. Cross-coupling between the oestrogen receptor and phosphoinositide 3-kinase. Biochem Soc Trans. 2003 Feb; 31(Pt 1):66-70. View in: PubMed

  181. Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol. 2002 Dec 01; 22(12):1952-61. View in: PubMed

  182. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest. 2002 Dec; 110(11):1729-38. View in: PubMed

  183. Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci U S A. 2002 Dec 10; 99(25):16197-202. View in: PubMed

  184. Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2003 Jan; 284(1):H133-40. View in: PubMed

  185. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002 Nov; 86(1):5-18. View in: PubMed

  186. Functional interaction of endothelial nitric oxide synthase with a voltage-dependent anion channel. Proc Natl Acad Sci U S A. 2002 Oct 01; 99(20):13108-13. View in: PubMed

  187. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002 Aug; 110(3):285-8. View in: PubMed

  188. 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res. 2002 Jul 12; 91(1):17-24. View in: PubMed

  189. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002 Jul 02; 106(1):57-62. View in: PubMed

  190. Statins and ischemic stroke. Atheroscler Suppl. 2002 May; 3(1):21-5. View in: PubMed

  191. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res. 2002 May 17; 90(9):1020-7. View in: PubMed

  192. Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants. J Biol Chem. 2002 Jul 19; 277(29):26460-7. View in: PubMed

  193. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002 May; 8(5):473-9. View in: PubMed

  194. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002 Mar 19; 105(11):1368-73. View in: PubMed

  195. Salicylates and vascular smooth muscle cell proliferation: molecular mechanisms for cell cycle arrest. Trends Cardiovasc Med. 2001 Nov; 11(8):339-44. View in: PubMed

  196. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001 Nov; 108(10):1429-37. View in: PubMed

  197. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 Nov; 21(11):1712-9. View in: PubMed

  198. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001 Apr; 32(4):980-6. View in: PubMed

  199. Regulation of myogenic terminal differentiation by the hairy-related transcription factor CHF2. J Biol Chem. 2001 May 25; 276(21):18591-6. View in: PubMed

  200. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001 May 11; 276(19):15983-9. View in: PubMed

  201. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000 May; 10(4):143-8. View in: PubMed

  202. Induction of endothelial-leukocyte interaction by interferon-gamma requires coactivation of nuclear factor-kappaB. Arterioscler Thromb Vasc Biol. 2001 Feb; 21(2):227-32. View in: PubMed

  203. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000 Dec 19; 102(25):3104-10. View in: PubMed

  204. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation. 2000 Oct 24; 102(17):2124-30. View in: PubMed

  205. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000 Sep 28; 407(6803):538-41. View in: PubMed

  206. Targeting Rho in cardiovascular disease. Circ Res. 2000 Sep 29; 87(7):526-8. View in: PubMed

  207. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res. 2000 Jul 07; 87(1):19-25. View in: PubMed

  208. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000 Jul; 106(1):15-24. View in: PubMed

  209. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab. 2000 Apr; 20(4):709-17. View in: PubMed

  210. A functional role of I kappa B-epsilon in endothelial cell activation. J Immunol. 2000 Mar 15; 164(6):3316-22. View in: PubMed

  211. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999 Aug 20; 285(5431):1276-9. View in: PubMed

  212. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999 Jul 30; 274(31):21926-31. View in: PubMed

  213. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999 Jul; 40(8):1808-12. View in: PubMed

  214. [Regulation of endothelial NO production by Rho GTPase]. Med Klin (Munich). 1999 Apr 15; 94(4):211-8. View in: PubMed

  215. Activation of guanine nucleotide-binding proteins and induction of endothelial tissue-type plasminogen activator gene transcription by alcohol. J Biol Chem. 1999 Apr 23; 274(17):12055-60. View in: PubMed

  216. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 1999 Apr 23; 274(17):11924-9. View in: PubMed

  217. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998 Sep 11; 273(37):24266-71. View in: PubMed

  218. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol. 1998 Aug 15; 161(4):1970-6. View in: PubMed

  219. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998 Jul 21; 95(15):8880-5. View in: PubMed

  220. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol. 1998 Jun; 63(6):732-9. View in: PubMed

  221. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 Mar 31; 97(12):1129-35. View in: PubMed

  222. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997 Dec 12; 272(50):31725-9. View in: PubMed

  223. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem. 1997 Dec 05; 272(49):30969-74. View in: PubMed

  224. [New findings on the action of HMG-CoA-reductase inhibitors]. Dtsch Med Wochenschr. 1997 Oct 10; 122(41):1255-9. View in: PubMed

  225. Hydrogen peroxide-mediated transcriptional induction of macrophage colony-stimulating factor by TGF-beta1. J Immunol. 1997 Sep 01; 159(5):2418-23. View in: PubMed

  226. Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide. J Biol Chem. 1997 Aug 01; 272(31):19601-8. View in: PubMed

  227. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J Clin Invest. 1995 Dec; 96(6):2661-6. View in: PubMed

  228. The G proteins of the G alpha i and G alpha q family couple the bradykinin receptor to the release of endothelium-derived relaxing factor. J Clin Invest. 1993 Nov; 92(5):2168-72. View in: PubMed

  229. Regulation of G-protein alpha i2 subunit expression by oxidized low-density lipoprotein. J Clin Invest. 1995 Apr; 95(4):1457-63. View in: PubMed

  230. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995 Jul; 96(1):60-8. View in: PubMed

  231. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991 Apr; 68(4):1027-34. View in: PubMed

  232. Acute myocardial infarction after ergonovine administration for uterine bleeding. Am J Cardiol. 1991 Sep 15; 68(8):823-4. View in: PubMed

  233. Specific receptor-guanine nucleotide binding protein interaction mediates the release of endothelium-derived relaxing factor. Circ Res. 1992 May; 70(5):1018-26. View in: PubMed
© 2023 The University of Chicago | All Rights Reserved.
Facebook Twitter Youtube